Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis

Cardiovascular Research

Volumn 98, Issue 3, 2013, Pages 402-410

  Poggio, Paolo ^a,b   Sainger, Rachana ^a   Branchetti, Emanuela ^a   Grau, Juan B ^a,c   Lai, Eric K ^a   Gorman, Robert C ^a   Sacks, Michael S ^d   Parolari, Alessandro ^b   Bavaria, Joseph E ^a   Ferrari, Giovanni ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d The University of Texas at Austin   (United States)

Author keywords

Aortic valve sclerosis; Bone morphogenetic protein 4; Calcific aortic stenosis; Valve interstitial cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIGLYCAN; BONE MORPHOGENETIC PROTEIN 4; COLLAGEN TYPE 1; DECORIN; NOGGIN; OSTEONECTIN; OSTEOPONTIN; PROTEOGLYCAN; TRANSCRIPTION FACTOR RUNX2;

ADULT; AORTA VALVE DISEASE; AORTA VALVE SCLEROSIS; AORTA VALVE STENOSIS; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MECHANICAL STIMULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION; VALVE INTERSTITIAL CELL;

AORTIC VALVE SCLEROSIS; BONE MORPHOGENETIC PROTEIN 4; CALCIFIC AORTIC STENOSIS; VALVE INTERSTITIAL CELLS;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOREACTORS; BONE MORPHOGENETIC PROTEIN 4; CALCINOSIS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL TRANSDIFFERENTIATION; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MECHANOTRANSDUCTION, CELLULAR; MIDDLE AGED; OSTEOGENESIS; PHENOTYPE; PRESSURE; RECOMBINANT PROTEINS; SCLEROSIS; TISSUE CULTURE TECHNIQUES; TISSUE ENGINEERING; TISSUE SCAFFOLDS; YOUNG ADULT;

EID: 84877975598     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt055     Document Type: Article

References (46)

1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-3326.
2. Kurtz CE, Otto CM. Aortic stenosis: clinical aspects of diagnosis and management, with 10 illustrative case reports from a 25-year experience. Medicine 2010; 89:349-379.
3. Beckmann E, Grau JB, Sainger R, Poggio P, Ferrari G. Insights into the use of biomar-kers in calcific aortic valve disease. J Heart Valve Dis 2010;19:441-452.
4. Otto CM. Calcific aortic valve disease: new concepts. Semin Thorac Cardiovasc Surg 2010;22:276-284.
5. Gharacholou SM, Karon BL, Shub C, Pellikka PA. Aortic valve sclerosis and clinical outcomes: moving toward a definition. Am J Med 2011;124:103-110.
6. Parolari A, Loardi C, Mussoni L, Cavallotti L, Camera M, Biglioli P et al. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur J Cardiothorac Surg 2009;35:493-504.
7. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-561.
8. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-2397.
9. Benton JA, Kern HB, Leinwand LA, Mariner PD, Anseth KS. Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression. Arterioscler Thromb Vasc Biol 2009;29:1950-1957.
10. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-1356.
11. Rossi R, Lidonnici MR, Soza S, Biamonti G, Montecucco A. The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway. Cancer Res 2006;66:1675-1683.
12. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart And Lung And Blood Institute Aortic Stenosis Working Group: executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124:1783-1791.
13. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohis-tochemical studies. Circulation 1994;90:844-853.
14. Grau JB, Poggio P, Sainger R, Vernick WJ, Seefried WF, Branchetti E et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg 2012;93:79-86.
15. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-147.
16. Mulholland DL, Gotlieb AI. Cell biology of valvular interstitial cells. Can J Cardiol 1996; 12:231-236.
17. Merryman WD, Youn I, Lukoff HD, Krueger PM, Guilak F, Hopkins RA et al. Correlation between heart valve interstitial cell stiffness and transvalvular pressure: implications for collagen biosynthesis. Am J Physiol Heart Circ Physiol 2006;290:H224-231.
18. Blevins TL, Carroll JL, Raza AM, Grande-Allen KJ. Phenotypic characterization of isolated valvular interstitial cell subpopulations. J Heart Valve Dis 2006;15:815-822.
19. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis 2004; 13:841-847.
20. Rabkin E, Hoerstrup SP, Aikawa M, Mayer JE, Schoen FJ. Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in-vitro maturation and in-vivo remodeling. J Heart Valve Dis 2002;11:308-314; discussion 314.
21. Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S et al. Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 1996;109 (Pt 6):1369-1380.
22. Sainger R, Grau JB, Branchetti E, Poggio P, Seefried WF, Field BC et al. Human myx-omatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation. J Cell Physiol 2012;227:2595-2604.
23. Branchetti E, Sainger R, Poggio P, Grau JB, Patterson-Fortin J, Bavaria JE et al. Antioxi-dant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis. Arterioscler Thromb Vasc Biol 2012;33:e66-e74.
24. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol 2009;296:H756-H764.
25. Mikhaylova L, Malmquist J, Nurminskaya M. Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a. Calcif Tissue Int 2007;81:372-381.
26. Sucosky P, Balachandran K, Elhammali A, Jo H, Yoganathan AP. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4and TGF-beta1-dependent pathway. Arterioscler Thromb Vasc Biol 2009;29:254-260.
27. Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M, Gabriel H et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 2004;25:199-205.
28. Sacks MS, David Merryman W, Schmidt DE. On the biomechanics of heart valve function. J Biomech 2009;42:1804-1824.
29. Rosenhek R, Iung B, Tornos P, Antunes MJ, Prendergast BD, Otto CM et al. ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. Eur Heart J 2012;33: 822-8-828a-828b.
30. Baumgartner H, Otto CM. Aortic stenosis severity: do we need a new concept? J Am Coll Cardiol 2009;54:1012-1013.
31. Balachandran K, Sucosky P, Yoganathan AP. Hemodynamics and mechanobiology of aortic valve inflammation and calcification. Int J Inflamm 2011;2011:263870.
32. Thayer P, Balachandran K, Rathan S, Yap CH, Arjunon S, Jo H et al. The effects of combined cyclic stretch and pressure on the aortic valve interstitial cell phenotype. Ann Biomed Eng 2011;39:1654-1667.
33. Merryman WD, Lukoff HD, Long RA, Engelmayr GC, Hopkins RA, Sacks MS. Syner-gistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol 2007;16:268-276.
34. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-617.
35. Allison DD, Drazba JA, Vesely I, Kader KN, Grande-Allen KJ. Cell viability mapping within long-term heart valve organ cultures. J Heart Valve Dis 2004;13:290-296.
36. Watson KE, Parhami F, Shin V, Demer LL. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998;18:1964-1971.
37. Mimori K, Komaki M, Iwasaki K, Ishikawa I. Extracellular signal-regulated kinase 1/2 is involved in ascorbic acid-induced osteoblastic differentiation in periodontal ligament cells. J Periodontol 2007;78:328-334.
38. Aikawa E, Otto CM. Look more closely at the valve: imaging calcific aortic valve disease. Circulation 2012;125:9-11.
39. Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004;13:560-566.
40. Pohjolainen V, Taskinen P, Soini Y, Rysä J, Ilves M, Juvonen T et al. Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol 2008;39:1695-1701.
41. Osman L, Yacoub MH, Latif N, Amrani M, Chester AH. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 2006; 114(Suppl. 1):I547-I552.
42. Yang X, Fullerton DA, Su X, Ao L, Cleveland JC, Meng X. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol 2009;53:491-500.
43. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am J Pathol 2010;177:49-57.
44. Shao ES, Lin L, Yao Y, Boström KI. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 2009;114:2197-2206.
45. Yip CYY, Simmons CA. The aortic valve microenvironment and its role in calcific aortic valve disease. Cardiovasc Pathol 2011;20:177-182.
46. Fokin VM, Yuritsyn NS, Zanotto ED. Nucleation theory and applications [Internet]. Weinheim, FRG: Wiley-VCH Verlag GmbH & Co. KGaA; 2005. http://onlinelibrary.wiley.com/doi/10.1002/3527604790.ch4/summary